Compare Quest Diagnostics Inc (DGX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Twilio Inc — how do they compare? Quest Diagnostics Inc trades at $237.59 (market cap $26.21B), while Twilio Inc trades at $246.16 (market cap $39.31B). The key difference: Twilio Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| DGX | TWLO | |
|---|---|---|
Market Cap | $26.21B | $39.31B |
Sector | Health | Technology |
52-Week High | $238.50 | $255.95 |
52-Week Low | $173.49 | $95.23 |
Enterprise Value | $31.97B | $37.72B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Twilio (TWLO) trades at $247.10, down 1.18% on the day, but remains near its 52-week high after a strong rally driven by Q2 2026 earnings beats and raised guidance. The stock shows bullish technical signals with support at $246 and resistance at $259. Revenue growth accelerated to 22% year-over-year in Q2, with net income turning positive in 2025 after years of losses, reflecting improved profitability and cash flow generation.
Outlook is positive with Wall Street consensus Buy rating and $266.31 price target, though high valuation multiples (P/E 35.35) and overbought RSI levels suggest near-term consolidation risk. Key opportunities include AI-driven growth and expanding free cash flow margins, while risks involve competitive pressures and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
